olivLaw · European equity research
Dr. Miele Cosmed Group Spółka Akcyjna DMG.WA
Poland · GPW Warszawa · ISIN PLGLBLC00011 · Vertical: Listed companies from Poland
At the close of 06 Nov 2026, Dr. Miele Cosmed Group Spółka Akcyjna (DMG.WA) stock was 1.85 PLN (+0.54% on the day), with market capitalisation 164.0 m PLN, P/E 7.4 on diluted EPS of 0.25 PLN over the last 12 months, dividend yield 1.63%, beta 0.18, 52-week range 1.84–3.19 PLN.
Data as of · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 33.5
- weak (30–45)
- Bollinger (20, 2)
- 1.81 – 2.02
- in the lower half of the band · %B 0.16 · band width 10.6%
- SMA 50 / 200
- 2.08 / 2.44
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.06 / -0.06
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | −10.9% | −0.6% | −10.2 pp | — |
| 3 months | −21.8% | −4.2% | −17.7 pp | — |
| 6 months | −20.8% | +4.3% | −25.2 pp | — |
| Year to date | −28.8% | +7.5% | −36.3 pp | — |
| 1 year | −42.3% | +9.9% | −52.3 pp | +5.9% |
| 3 years | −39.5% | +49.8% | −89.4 pp | +1.8% |
| 5 years | −58.2% | +42.8% | −101.0 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 0 percentile of its own 2-quarter history (min 12.7, median 24.0, max 35.3; quarters with earnings only).
Fiscal years
| Fiscal year | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue | 351.9 m | 396.6 m | 444.5 m |
| Revenue YoY | unavailable | +12.7% | +12.1% |
| Net income | 11.6 m | -2.3 m | 22.2 m |
| Net income YoY | unavailable | −119.5% | unavailable |
| Diluted EPS | 0.13 | -0.03 | 0.25 |
| Diluted EPS YoY | unavailable | −123.1% | unavailable |
| net % | 3.3% | -0.6% | 5.0% |
| Free cash flow | 8.4 m | -753.0 k | 21.6 m |
Balance sheet & financial health
Fiscal year 2023 · 31 Dec 2023
- Cash
- 14.3 m PLN
- Financial debt
- 7.5 m PLN
- Net debt
- -6.8 m PLN
- Equity
- 234.4 m PLN
- Total assets
- 382.4 m PLN
- Debt / equity
- 0.03x
- Current ratio
- 1.02x
- ROE
- 9.9%
- ROA
- 5.9%
- FCF margin
- 4.9%
Financial statements (source on every figure)
Revenue and net income (PLN)
Margins
Income statement · PLN
| Line | 2021 | 2022 | 2023 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 351.9 m | 396.6 m | 444.5 m | esef· 02 May 2024verified |
| Gross profit | 13.7 m | 2.0 m | 33.2 m | esef· 02 May 2024verified |
| Operating income | 15.1 m | 1.3 m | 33.0 m | esef· 02 May 2024verified |
| Depreciation & amortisation | 10.6 m | 11.3 m | 12.0 m | esef· 02 May 2024verified |
| EBITDA | 25.7 m ≈ | 12.6 m ≈ | 45.0 m ≈ | esef· 02 May 2024derived |
| Interest expense | 2.1 m | 3.8 m | 6.0 m | esef· 02 May 2024verified |
| Pre-tax income | 13.3 m | -2.1 m | 27.2 m | esef· 02 May 2024verified |
| Income tax | 1.7 m | 170.0 k | 5.0 m | esef· 02 May 2024verified |
| Net income | 11.6 m | -2.3 m | 22.2 m | esef· 02 May 2024verified |
| Diluted EPS | 0.13 | -0.03 | 0.25 | esef· 02 May 2024verified |
| Weighted average diluted shares | 87.3 m | 87.3 m | 87.3 m | esef· 02 May 2024verified |
| Dividend per share | — | 0.03 | — | esef· 17 May 2023verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · PLN
| Line | 2021 | 2022 | 2023 | Source (latest year) |
|---|---|---|---|---|
| Cash | 11.3 m | 9.4 m | 14.3 m | esef· 02 May 2024verified |
| Inventories | 42.0 m | 53.6 m | 51.1 m | esef· 02 May 2024verified |
| Current assets | 104.6 m | 114.5 m | 121.2 m | esef· 02 May 2024verified |
| Property, plant & equipment, net | 132.9 m | 136.1 m | 132.9 m | esef· 02 May 2024verified |
| Goodwill | 30.1 m | 30.1 m | 30.1 m | esef· 02 May 2024verified |
| Intangibles (excl. goodwill) | 94.1 m | 93.7 m | 93.5 m | esef· 02 May 2024verified |
| Total assets | 361.6 m | 374.3 m | 382.4 m | esef· 02 May 2024verified |
| Long-term debt | 15.9 m | 150.0 k | 7.5 m | esef· 02 May 2024verified |
| Current liabilities | 111.6 m | 139.0 m | 118.5 m | esef· 02 May 2024verified |
| Total liabilities | 144.1 m | 161.7 m | 148.0 m | esef· 02 May 2024verified |
| Equity | 217.5 m | 212.6 m | 234.4 m | esef· 02 May 2024verified |
| Shares outstanding at year end | 89.2 m | 75.5 m | 88.9 m | esef· 02 May 2024derived |
Cash flow · PLN
| Line | 2021 | 2022 | 2023 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | 26.1 m | 5.8 m | 31.3 m | esef· 02 May 2024verified |
| Capex | 17.7 m | 6.6 m | 9.7 m | esef· 02 May 2024verified |
| Free cash flow | 8.4 m ≈ | -753.0 k ≈ | 21.6 m ≈ | esef· 02 May 2024derived |
| Investing cash flow | -17.4 m | 602.0 k | -12.9 m | esef· 02 May 2024verified |
| Financing cash flow | -15.5 m | -8.3 m | -13.4 m | esef· 02 May 2024verified |
| Share repurchases | 1.1 m | 31.0 k | 0 | esef· 02 May 2024verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 70 / 100
A scoring methodology on indicators and valuation, not investment advice.
score >= 65 · margin_of_safety >= 0.15 · agreement in ['high', 'medium']
Closing price
06 Nov 2026Source: olivLaw, closing series
Market cap: 164.0 m PLN
Key indicators
Coverage and freshness
The data is older than the freshness threshold.
Score by group
- Quality60
- Balance sheet72
- Valuation91
- Returns0
Estimated value range
unavailable — no valuation assumptions for the reporting currency
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
Assumptions (illustrative, editorial)
- Risk-free rate
- 6.5%
- Equity risk premium
- 6.0%
- Beta (default)
- 1.00
- Cost of equity
- 12.5%
- Terminal growth
- 3.0%
Factor scorecard
Attractive profile · Score 70/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 12.5% | 40 (vs peers) | 13% |
| Net margin · Quality | 5.0% | 56 (vs peers) | 8% |
| FCF conversion · Quality | 97.0% | 96 (on a fixed band) | 8% |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | -0.2x | 100 (on a fixed band) | 13% |
| Interest coverage · Balance sheet | 5.5x | 61 (on a fixed band) | 8% |
| Current ratio · Balance sheet | 1.0x | 19 (on a fixed band) | 5% |
| P/E (TTM) · Valuation | 7.4x | 74 (vs peers) | 13% |
| EV/EBITDA · Valuation | 3.5x | 100 (on a fixed band) | 13% |
| FCF yield · Valuation | 13.1% | 100 (on a fixed band) | 11% |
| Shareholder yield (distributions) · Returns | 0.0% | 0 (on a fixed band) | 8% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet72/100 · 3/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality60/100 · 3/3 factors with a value
- Returns· partial0/100 · 1/2 factors with a value
- Valuation91/100 · 3/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
DR. MIELE COSMED GROUP SPÓŁKA AKCYJNA (DMG.WA). Latest full fiscal year: 2023; data up to 2023-12-31.
Figures computed from the financial statements: revenue 444.5 m PLN in 2023; YoY growth 12.1%; net margin 5.0%; ROE 9.9%; net debt/EBITDA -0.2x.
The estimated value range is 2.54–4.59 PLN per share (median of 2 methods, agreement: high); assumptions are illustrative. Against the central value of 3.34 PLN, the price of 1.84 PLN leaves a potential of 81.0% (value / price − 1) and a margin of safety of 44.7% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 70/100, methodological classification: attractive profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: growth, returns. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- FCF conversion: 97.0%
- Net debt / EBITDA: -0.2x
- P/E (TTM): 7.4x
- EV/EBITDA: 3.5x
- FCF yield: 13.1%
- The price is below the estimated value range
What contradicts it
- Current ratio: 1.0x
- Shareholder yield (distributions): 0.0%
Not assessed (insufficient data or a ratio without meaning): Revenue CAGR 3Y, EPS CAGR 3Y, Payout ratio (FCF).
Versus the vertical median
Listed companies from Poland · same country · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ACP.WAAsseco Poland S.A. | 19.0 bn | 37.8 | 7.8% | 2.9% | +19.8% | +18% / +199% |
| BDX.WABudimex Spółka Akcyjna | 18.9 bn | 35.3 | 41.5% | 6.2% | +8.9% | +18% / +33% |
| BFT.WABenefit Systems Spółka Akcyjna | 18.1 bn | 130.7 | 20.8% | 7.2% | +99.9% | +74% / +221% |
| ASE.WAAsseco South Eastern Europe Spółka Akcyjna | 3.7 bn | 19.6 | 18.1% | 12.0% | +36.5% | +6% / +50% |
| 1AT.WAAtal Spółka Akcyjna | 2.3 bn | 6.4 | 29.8% | 22.2% | −1.3% | +7% / +8% |
| ATT.WAGrupa Azoty Spółka Akcyjna | 1.6 bn | — | -37.9% | -20.8% | −45.1% | −15% / −26% |
| ARH.WAArchicom Spółka Akcyjna | 1.3 bn | 12.1 | 15.9% | 22.1% | −21.6% | +13% / +88% |
| ACT.WAAction S.A. | 999.4 m | 27.2 | 8.3% | 1.5% | +6.1% | +71% / +171% |
| BRS.WABoryszew Spółka Akcyjna | 874.1 m | 8.2 | 6.3% | 1.6% | +8.4% | −25% / −28% |
| AGO.WAAgora Spółka Akcyjna | 588.0 m | — | -14.2% | -9.2% | +15.2% | +37% / +18% |
| AMB.WAAmbra S.A. | 462.9 m | 7.5 | 16.4% | 7.0% | +12.9% | +4% / −33% |
| ATC.WAArctic Paper Spółka Akcyjna | 344.7 m | 1.4 | 16.3% | 7.0% | −27.5% | −40% / −75% |
| ATG.WA"atm Grupa Spółka Akcyjna" | 298.5 m | 11.0 | 8.9% | 11.6% | −22.0% | −11% / +2% |
| ART.WAArtifex Mundi S.A. | 229.7 m | 17.7 | 35.7% | 33.3% | +51.9% | +48% / +14% |
| APN.WAAPLISENS Spółka Akcyjna | 192.4 m | 9.4 | 11.4% | 13.8% | +21.8% | −2% / −22% |
| DMG.WADr. Miele Cosmed Group Spółka Akcyjna | 164.0 m | 7.4 | 9.9% | 5.0% | +12.1% | −39% / −49% |
| ALI.WAALTUS Spolka Akcyjna | 158.1 m | 17.3 | 7.9% | 16.9% | +30.3% | +38% / +52% |
| BMC.WABumech Spółka Akcyjna | 156.9 m | — | -3.4% | -3.9% | −40.0% | −36% / −49% |
| BBT.WABoomBit Spółka Akcyjna | 71.9 m | 4.5 | 20.7% | 6.4% | −16.5% | −18% / −56% |
| BBD.WABbi Development S.A. | 54.1 m | 1.1 | 36.0% | 208.3% | +50.2% | +1% / +9% |
| ALG.WAAll in! Games Spółka Akcyjna | 39.6 m | — | — | -156.9% | −72.2% | −27% / −56% |
| BMX.WABioMaxima Spółka Akcyjna | 36.3 m | 62.0 | 1.2% | 1.3% | −67.5% | −31% / −46% |
| 06N.WAMagna Polonia Spółka Akcyjna | 31.1 m | 0.5 | 115.4% | 964.7% | +13.0% | −29% / −43% |
| BCM.WABETACOM Spółka Akcyjna | 26.3 m | 17.3 | 8.0% | 0.9% | +21.3% | +6% / +2% |
| AWM.WAAirway Medix Spółka Akcyjna | 13.8 m | — | -25.8% | -117,400.0% | −97.7% | −26% / −45% |
1- and 3-year price returns: for DMG.WA from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (PLN)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 1.17 Total return -35% · Per year -35% | 2.07 Total return 14% · Per year 14% | 3.11 Total return 70% · Per year 70% |
| 3 years | 1.32 Total return -24% · Per year -9% | 2.60 Total return 47% · Per year 14% | 4.26 Total return 138% · Per year 34% |
| 5 years | 1.48 Total return -12% · Per year -2% | 3.26 Total return 88% · Per year 14% | 5.83 Total return 232% · Per year 27% |
- Exit P/E± 0.65
- Net margin± 0.45
- Annual revenue growth± 0.35
- Annual dilution± 0.04
AI analysis
The qualitative analysis has not been written for this company yet.
Products, market & competition
The qualitative analysis has not been written for this company yet.
News & filings
In the press
No news in our archive over the last 180 days.
Annual reports (ESEF)
- Annual report 202302 May 2024
- Annual report 202217 May 2023
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.